Alcohol and drugs

Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome

Abstract Background Alcohol abuse and dependence represents a very serious health problem worldwide with major social, interpersonal and legal interpolations. Pharmacological treatments presently used are of uncertain effectiveness and there is even more doubt on the comparative effects and value for money. Objectives To summarize Cochrane reviews that assess the effectiveness and safety of pharmacological […]

Share

Oral naltrexone maintenance treatment for opioid dependence

Abstract Background Research on clinical application of oral naltrexone agrees on several things. From a pharmacological perspective, naltrexone works. From an applied perspective, the medication compliance and the retention rates are poor. Objectives To evaluate the effects of naltrexone maintenance treatment versus placebo or other treatments in preventing relapse in opioid addicts after detoxification. Search […]

Share

Treatment for inhalant dependence and abuse

Abstract Background Inhalants are being abused by large numbers of people throughout the world, particularly socio-economically disadvantaged children and adolescents. The neuropsychological effects of acute and chronic inhalant abuse include motor impairment, alterations in spontaneous motor activity, anticonvulsant effects, anxiolytic effects, sensory effects, and effects and learning, memory and operant behaviour (e.g., response rates and […]

Share

Opioid antagonists for alcohol dependence

Abstract Background Alcohol dependence belongs to the globally leading health risk factors. Therapeutic success of psychosocial programs for relapse prevention is moderate and could be increased by an adjuvant treatment with the opioid antagonists naltrexone and nalmefene. Objectives To determine the effectiveness and tolerability of opioid antagonists in the treatment of alcohol dependence. Search methods […]

Share

Pharmacological treatment for depression during opioid agonist treatment for opioid dependence

Abstract Background Lifetime prevalence of depression in subjects with opioid dependence is higher than in the general population (44-54% versus 16%) and represents a risk factor for morbidity and mortality. For patients on opioid agonist treatment, current prevalence rates of depression ranges between 10 and 30%, influencing negatively the outcome of the treatment. Objectives To […]

Share

Acamprosate for alcohol dependence

Abstract Background Alcohol dependence is among the main leading health risk factors in most developed and developing countries. Therapeutic success of psychosocial programs for relapse prevention is moderate, but could potentially be increased by an adjuvant treatment with the glutamate antagonist acamprosate. Objectives To determine the effectiveness and tolerability of acamprosate in comparison to placebo […]

Share

Benzodiazepines for alcohol withdrawal

Abstract Background Alcohol abuse and dependence represents a serious health problem worldwide with social, interpersonal and legal interpolations. Benzodiazepines have been widely used for the treatment of alcohol withdrawal symptoms. Moreover it is unknown whether different benzodiazepines and different regimens of administration may have the same merits. Objectives To evaluate the effectiveness and safety of […]

Share

Anticonvulsants for alcohol withdrawal

Abstract Background Alcohol abuse and dependence represents a most serious health problem worldwide with major social, interpersonal and legal interpolations. Besides benzodiazepines, anticonvulsants are often used for the treatment of alcohol withdrawal symptoms. Anticonvulsants drugs are indicated for the treatment of alcohol withdrawal syndrome, alone or in combination with benzodiazepine treatments. In spite of the […]

Share

Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses

Abstract Background Chronic excessive alcohol consumption may lead to dependence, and to alcohol withdrawal syndrome (AWS) in case of abrupt drinking cessation. Gamma-hydroxybutyric acid (GHB) can prevent and suppress withdrawal symptoms, and improve the medium-term abstinence rate. However, clear estimates of its beneficial and harmful effects have not been yet established. Objectives To evaluate the […]

Share

Disulfiram for the treatment of cocaine dependence

Abstract Background Cocaine dependence is a disorder for which no pharmacological treatment of proven efficacy exists, advances in the neurobiology could guide future medication development. Objectives To evaluate the efficacy and the acceptability of disulfiram for cocaine dependence. Search methods We searched: PubMed, EMBASE, CINAHL (up to January 2008), the Cochrane Central Register of Controlled […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share